Fig. 1From: Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trialPatient flow chart. ICF informed consent form, AE adverse event, AMI acute myocardial infarctionBack to article page